FedEx Corp. (NYSE: FDX) has launched FedEx Life Sciences, a specialized organization designed to meet the evolving logistics needs of the healthcare industry, including the transportation of pharmaceuticals, medical devices, biologics, clinical trial materials, and other critical healthcare products.

As healthcare continues to advance toward more personalized, global, and time-sensitive treatments, life sciences companies require logistics solutions that provide enhanced precision, visibility, and dependability. FedEx Life Sciences is designed to address these demands by combining specialized healthcare expertise, advanced monitoring technologies, and the company’s extensive global transportation network.

The new organization will support healthcare customers by helping manage complex supply chains involving temperature-controlled therapies, clinical research shipments, medical equipment, and patient-critical deliveries across highly regulated markets worldwide.

“Transporting vital healthcare deliveries requires more than just standard logistics. It depends upon an intelligent, highly specialized network built for patient-critical needs,” said Brie Carere, executive vice president and chief customer officer, FedEx. “Every shipment we move in this space has the potential to support a researcher, a medical professional, or most importantly, a patient waiting for care. To meet these critical demands, FedEx Life Sciences brings together our global network, advanced monitoring, and specialized expertise to make supply chains smarter and more resilient. Under Nick’s leadership, this team will help our customers deliver with the absolute speed, confidence, and precision that patients rely on.”

Nick Gennari has been appointed president of healthcare and life sciences and will lead the newly dedicated business segment. Gennari, who joined FedEx in 1992, brings more than three decades of experience developing supply chain and logistics solutions for healthcare, aerospace, and high-tech industries. Since taking leadership of the healthcare vertical in 2024, he and his team have played a key role in expanding FedEx’s healthcare business, which now generates approximately $10 billion in global revenue.

“Healthcare supply chains are becoming more complex, and the stakes are deeply personal,” said Nick Gennari, president of healthcare and life sciences, FedEx. “FedEx Life Sciences gives our customers a more focused team, stronger coordination, and specialized expertise to help them move critical healthcare shipments with confidence. Our role is to provide the certainty, visibility, and global reach healthcare innovators need when every shipment matters.”

The launch of FedEx Life Sciences builds on the company’s continued investment in healthcare infrastructure, quality standards, and technology. In 2025, FedEx achieved IATA CEIV Pharma Corporate Certification, recognizing its commitment to pharmaceutical handling standards across its global air hubs and ramps. The company has also strengthened its healthcare leadership structure with the appointment of a vice president of global quality, healthcare, and life sciences to oversee quality management systems and support pharmaceutical and medical device requirements.

FedEx continues to expand its global life sciences network, with six dedicated Life Sciences Centers supporting customers worldwide. The company has also enhanced international pharmaceutical connectivity through the launch of a direct flight between Indianapolis and Dublin, linking two major pharmaceutical manufacturing hubs.

Supporting these capabilities is FedEx Surround, an advanced monitoring and intervention platform that uses machine learning to provide real-time shipment visibility, identify potential disruptions, and enable proactive action when temperature control, timing, and reliability are critical.

Through FedEx Life Sciences, the company aims to provide healthcare organizations with the specialized logistics expertise and technology needed to support the next generation of healthcare delivery.